Join Us: 2nd Annual NYC Prostate Cancer Summit

ProstateCancerSummit_Postcard.BlogThe Inaugural New York City Prostate Cancer Summit in 2018 granted us the ability to educate and empower nearly 250 prostate cancer patients, loved ones, healthcare professionals and community members with the latest updates in the field. Following the success of last year’s event, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center and Memorial Sloan Kettering Cancer Center are joining forces again to host the 2nd Annual NYC Prostate Cancer Summit on Saturday, September 21, 2019. 

The Summit will take place from 8AM – 2PM at the New York Academy of Medicine on 1216 5th Avenue, New York, NY 10029. The event is free and open to all patients and loved ones impacted by prostate cancer.

RSVP is required. Reserve your seat today:

We are pleased to offer a fresh slate of presentations based on audience suggestions from last year’s event. Here’s your first look at the topics on tap.

Introductory remarks by David Nanus, MD, of Weill Cornell Medicine/NewYork-Presbyterian Hospital 

The Latest Therapies and Technologies for Diagnosing and Treating Prostate Cancer

Cora Sternberg, MD – Treatment Overview
Weill Cornell Medicine

Jim Hu, MD – Focal Therapy
Weill Cornell Medicine

Sean McBride, MD – Hypofractionation (short course) Radiation
Memorial Sloan Kettering Cancer Center

Charles Drake, MD, PhD – Immunotherapy and Other Targeted Therapies
Columbia University Irving Medical Center

Moderated by Mark Stein, MD, of Columbia University Irving Medical Center

What Your Genes Really Mean: Examining Family History, Prognosis and Outcomes

Feighanne Hathaway, MS, CGC
University of Chicago Medicine

Coping with Side Effects and Maximizing Quality of Life

Joseph Alukal, MD – Sexual Health and Incontinence
Columbia University Irving Medical Center

Guy Maytal, MD – Anxiety
Weill Cornell Medicine

Moderated by Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center

Is A Clinical Trial Right for You? Advancing Prostate Cancer Research

Scott Tagawa, MD, MS, Weill Cornell Medicine

Dina Lansey, MSN, RN, Johns Hopkins Sidney Kimmel Cancer Center

Ed Randall, Fans for the Cure

Moderated by Jonathan W. Simons, MD, of the Prostate Cancer Foundation


Inaugural NYC Prostate Cancer Summit

Over 200 prostate cancer patients and loved ones from across the Tri-State Area attended our Inaugural New York City Prostate Cancer Summit last year. The education and advocacy event was a collaboration among Manhattan’s top academic medical institutions: Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center and Memorial Sloan Kettering Cancer Center. Local medical experts and national advocacy leaders came together to discuss topics including immunotherapy, screening, coping with anxiety and much more.

In case you missed the Summit, check out the video recaps below, and mark your calendar for our Second Annual Summit on Saturday, September 21, 2019.

Premier MRI-Guided Radiotherapy Technology Enables Real-Time Tumor Tracking

Radiotherapy is a core element of prostate cancer treatment, yielding cures in men with localized disease. The goal of prostate cancer radiotherapy is to deliver high doses of radiation to the prostate gland while avoiding the surrounding bladder and rectum, thus preventing unwanted urinary and gastrointestinal side effects and preserving patient quality of life.

Radiotherapy guided by magnetic resonance imaging (MRI) allows clinicians to visualize a tumor as well as its neighboring organs in order to most accurately deliver treatment to the target region.

Weill Cornell Medicine and NewYork-Presbyterian Hospital (WCM/NYP) are proud to be the first – and only – medical institution in the northeast to offer patients the most premier MRI-guided radiotherapy technology available: the MRIdian Linear Accelerator, by ViewRay. The MRIdian Linac’s unique ability to track a patient’s tumor in real time during treatment makes it by far the most advanced modality of delivering radiation.

Real-time visualization is significant due to the constant flux of internal human anatomy, including changes in respiration, digestion and bladder fill that can influence the position of the prostate within the body. Even a minor shift of the tumor target during treatment can have major implications related to potential side effects of radiation. If the bladder or rectum displace the prostate during treatment, the MRIdian Linac machine will cease delivery of radiation and not resume until the prostate moves back in bounds of the target region. Whereas other modalities track small fiducial markers implanted in the prostate, this machine allows clinicians to see and track the tumor itself.

In addition, WCM/NYP is the only center in the area to offer combined use of MRI-guided radiotherapy with the rectal SpaceOAR, a hydrogel barrier that is temporarily placed between the prostate and rectum to shield the rectum from radiation and further reduce potential side effects.

Watch the video below to learn more about this state-of-the-art technology from WCM/NYP radiation oncologist Dr. Himanshu Nagar.